KRW 9030.0
(1.46%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 18.16 Billion KRW | 36.71% |
2022 | 12.3 Billion KRW | 18.59% |
2021 | 10.37 Billion KRW | 24.86% |
2020 | 8.3 Billion KRW | -9.76% |
2019 | 9.2 Billion KRW | -11.31% |
2018 | 10.38 Billion KRW | 107.57% |
2017 | 5 Billion KRW | -88.1% |
2016 | 42.05 Billion KRW | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 4.97 Billion KRW | -8.55% |
2024 Q2 | 4.04 Billion KRW | -8.37% |
2023 Q1 | 3.76 Billion KRW | 3.77% |
2023 Q2 | 3.24 Billion KRW | -13.84% |
2023 Q3 | 4.37 Billion KRW | 34.75% |
2023 Q4 | 5.43 Billion KRW | 24.32% |
2023 FY | 16.82 Billion KRW | 36.71% |
2022 Q2 | 2.75 Billion KRW | 2.18% |
2022 FY | 12.3 Billion KRW | 18.59% |
2022 Q4 | 3.62 Billion KRW | 14.35% |
2022 Q3 | 3.17 Billion KRW | 15.26% |
2022 Q1 | 2.69 Billion KRW | -9.64% |
2021 FY | 10.37 Billion KRW | 24.86% |
2021 Q4 | 2.98 Billion KRW | 17.77% |
2021 Q3 | 2.53 Billion KRW | 0.0% |
2020 FY | 8.3 Billion KRW | -9.76% |
2019 FY | 9.2 Billion KRW | -11.31% |
2018 FY | 10.38 Billion KRW | 107.57% |
2017 FY | 5 Billion KRW | -88.1% |
2016 FY | 42.05 Billion KRW | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 78.35 Billion KRW | 76.821% |
InBody Co.,Ltd | 87.36 Billion KRW | 79.21% |
Seegene, Inc. | 210.08 Billion KRW | 91.354% |
i-SENS, Inc. | 91.12 Billion KRW | 80.069% |
Ray Co., Ltd. | 59.03 Billion KRW | 69.232% |
Gencurix Inc. | 12.79 Billion KRW | -41.92% |
Sugentech Inc. | 18.6 Billion KRW | 2.368% |
L&C Bio Co., Ltd | 25.86 Billion KRW | 29.766% |